Risk-reducing mastectomy in BRCA carriers: survival is not the issue.

P Neven, K Punie, H Wildiers, N Willers, C Van Ongeval, G Van Buggenhout, E Legius

Abstract readLetterComment

In one paragraph

Article in Breast cancer research and treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

Counselling Framework for GermlineCurrent oncology (Toronto, Ont.) · 2024
Review
Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients.Scientific reports · 2021
Article
Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants inJournal of oncology · 2020
Review

4 · The record

Corrections and comments

Commented on by
Risk-reducing mastectomy in BRCA mutation carriers: survival is one of the issues-author's reply.2020
Comment on
Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.2019

5 · Who and what money

Authors and funding

7 authors.

P NevenMultidisciplinary Breast Centre and Leuven University Centre for Cancer Prevention (LUCK), University Hospitals Leuven, Louvain, Belgium. Patrick.neven@uzleuven.be.ORCID 0000-0002-1434-9460

K PunieMultidisciplinary Breast Centre and Leuven University Centre for Cancer Prevention (LUCK), University Hospitals Leuven, Louvain, Belgium.

H WildiersMultidisciplinary Breast Centre and Leuven University Centre for Cancer Prevention (LUCK), University Hospitals Leuven, Louvain, Belgium.

N WillersMultidisciplinary Breast Centre and Leuven University Centre for Cancer Prevention (LUCK), University Hospitals Leuven, Louvain, Belgium.

C Van OngevalMultidisciplinary Breast Centre and Leuven University Centre for Cancer Prevention (LUCK), University Hospitals Leuven, Louvain, Belgium.

G Van BuggenhoutDepartment of Human Genetics, University Hospitals Leuven, Louvain, Belgium.

E LegiusMultidisciplinary Breast Centre and Leuven University Centre for Cancer Prevention (LUCK), University Hospitals Leuven, Louvain, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Genes, BRCA2MastectomyHeterozygote

Identifiers

PMID31541380

DOI10.1007/s10549-019-05440-4

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.